Skip to main content
. Author manuscript; available in PMC: 2010 Jul 7.
Published in final edited form as: Antivir Ther. 2010;15(4):661–675. doi: 10.3851/IMP1573

Table 1.

Results from all combination treatment studies.

Time to >5% Weight Loss Overall Weight Loss Clinical Score Survival
Study 1 (n=5 or 6)
  Combo vs. PBS P=0.049 P=0.003 P=0.003 P=0.0005
  Combo vs. VIG P=0.82 P=0.06 P=0.006 P=0.005
Study 2 (n=5)
 Combo vs. control mAb P=0.02 P=0.017 P<0.0001 P=0.003
  Combo vs. VIG P=0.15 P=0.98 P=0.01 P=0.49
Study 3 (n=10)
 Combo vs. control mAb P=0.0009 P=0.0006 P<0.0001 P<0.0001
  Combo vs. VIG P=0.07 P=0.04 P=0.06 P=0.03
  Combo vs. C12 P=0.34 P=0.16 P=0.42 P=0.22
  Combo vs. D67 P=0.19 P=0.051 P=0.16 P=0.036
Study 4 (n=10)
 Combo vs. control mAb P<0.0001 P<0.0001 P<0.0001 P=0.0015
  Combo vs. VIG P=0.0009 P=0.039 P=0.0036 P=0.14
  Combo vs. C12 P=0.084 P=0.40 P=0.03 P=0.37
Meta-Analysis
 Combo vs. control mAb P<0.0001 P<0.0001 P<0.0001 P<0.0001
  Combo vs. VIG P=0.0002 P=0.0004 P=0.0006 P=0.0003
  Combo vs. C12 P=0.046 P=0.049 P=0.096 P=0.006